Medx Health Corp (MDXHF) 0.0668 $MDXHF
MedX Health Corp. Announces Second Quarter 2014 Financial Results
Marketwire - Wed Aug 27, 8:04PM CDT
MedX Health Corp. ("MedX" or the "Company"
(TSX VENTURE: MDX), dedicated to the early detection of skin cancer, announced its results for the three and six months ended June 30, 2014, which are also available on SEDAR (www.sedar.com).
MedX Health Corp. Announces Approval of Debt Settlement and AGM Results
Marketwire - Wed Jun 25, 9:40PM CDT
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX) announces that at its Annual and Special Meeting of Shareholders held on June 24, 2014, all resolutions proposed to shareholders were duly passed, including the approval of the issuance of 1,742,415 common shares relating to a settlement in November, 2013 of $435,603 of debt due to insiders of the Company. During the meeting, Gary Van Nest, David Hennigar, Steven Guillen, Ken McKay and Robert von der Porten were re-elected to the Board of Directors.
MedX Health Corp. Announces Extension of Private Placement
Marketwire - Mon Mar 24, 6:40PM CDT
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX) announces that it has extended, to April 11, 2014, the date for closing of a further tranche of the private placement of units ("Unit(s)" , in respect of which the first tranche, which raised $565,000, was closed on March 19, 2014. As previously, Trapeze Capital Corp., is acting as lead agent (the "Agent" . Each Unit comprises one common share and one share purchase warrant (a "Warrant" at $0.10 per Unit. Each Warrant entitles the holder to purchase one additional common share during the period expiring two years following closing at $0.20 per share. MedX will pay the Agent a cash commission of 8% of cash raised, subject to a reduced rate in respect of subscribers on the "President's List", and will issue broker warrants to the Agent equal in number to 8% of the Units issued. Each broker warrant will be exercisable at $0.10 to acquire a unit comprising one common share and one share purchase warrant exercisable to acquire an additional common share from treasury at an exercise price of $0.20; the broker warrants and the share purchase warrants underlying the broker warrants will expire two years after the closing of the placement. Any shares comprised in the Units and the Warrants and any shares issued on exercise of the Warrants or the broker warrants or the share purchase warrants underlying the units in the broker warrants will be restricted from trading for a period of four months and one day from the date of closing of the issue.
MedX Health Corp. Announces Closing of First Tranche of Private Placement
Marketwire - Wed Mar 19, 5:16PM CDT
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX) announces that it has closed on a first tranche of a private placement, as previously announced on January 22, 2014. Trapeze Capital Corp., acted as lead agent (the "Agent" , to raise gross proceeds of up to $2.0 million, from accredited investors, on a reasonable efforts basis through a private placement of Units. The first tranche which was closed today, raised gross proceeds of $565,000 to its treasury by issuance of 5,650,000 units, comprising 5,650,000 common shares and 5,650,000 share purchase warrants ("Warrants" at $0.10 per unit. Each Warrant entitles the holder to purchase one additional common share during the period expiring March 19, 2016, at $0.20 per share. The securities issued through the private placement were subscribed for by accredited investors, and are restricted from trading before July 20, 2014. At closing, MedX paid the Agent a cash commission of $24,200, and issued 452,000 broker warrants to the Agent. Each broker warrant will be exercisable at $0.10 to acquire a unit comprising one common share and one share purchase warrant exercisable to acquire an additional common share from treasury at an exercise price of $0.20; the broker warrants and the share purchase warrants underlying the broker warrants will expire on March 19, 2016. Any shares issued on exercise of the broker warrants or the share purchase warrants underlying the units in the broker warrants will be restricted from trading until July 20, 2014.
MedX Health Corp. Announces CE Mark for Its MOLEMATE(TM)/SIMSYS(TM) Skin Cancer Imaging Systems
Marketwire - Wed Feb 12, 10:50AM CST
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX), a leader in skin cancer imaging and diagnostics, announced receipt of a CE Mark from Conformite Europeenne, which allows the Company to market its MoleMate and SIMSYS systems in Europe to dermatologists and to expand further its pharmacy-based sales channel.
MedX Health Corp. Announces Brokered Private Placement
Marketwire - Wed Jan 22, 9:19AM CST
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX) announces the engagement of Trapeze Capital Corp., as lead agent (the "Agent" , to raise gross proceeds of up to $2.0 million, from accredited investors, on a reasonable efforts basis through a private placement of Units, with each Unit comprised of one Common Share and one Common Share Purchase Warrant ('Warrant" (the "Offering" at $0.10 per Unit. Each Warrant will entitle the holder to purchase one Common Share during the period ending two years from the date of issue, at an exercise price of $0.20.
MedX Health Corp. Announces Proposed Private Placement to Raise $203,000
Marketwire - Fri Dec 20, 3:36PM CST
MedX Health Corp. ("MedX" or the "Company" (TSX VENTURE: MDX) announces that it has entered into private placement agreements with accredited investors to raise a total of $203,000 by issuance of a total of 2,030,000 Units at $0.10 per unit. Each Unit comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at the price of $0.20 during the period expiring December 31, 2014. Closing of the Placement is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange.
MedX Health Corp. results for the Second Quarter of fiscal 2013
CNW Group - Tue Aug 27, 10:06PM CDT
TSX Venture Symbol: MDX
MedX Health Corp. Announces Share Issuance Pursuant To Debt Settlement Agreements And Also Grant Of Stock Options
CNW Group - Fri Jul 19, 3:51PM CDT
TSX Venture Symbol: MDX
MedX Health Corp. reaches agreements to settle debts of $362,078
CNW Group - Thu Jul 04, 2:23PM CDT
TSX Venture Symbol: MDX CUSIP #: 585090
MedX Health Reports 2012 and First Quarter 2013 Financial Results
CNW Group - Fri Jun 07, 11:29AM CDT
MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy for tissue repair and pain relief have reported their revenues for 2012 and the first quarter of 2013. Please see www.SEDAR.com for the actual filings.
IIROC Trading Resumption - MDX
CNW Group - Fri May 31, 3:27PM CDT
Trading resumes in:
IIROC: Resume, OREMEX SILVER INC., MEDX HEALTH CORP.
Marketwire Canada - Fri May 31, 3:25PM CDT
Trading resumes in / Reprise des negociations pour :
MedX Health Corp. Announces Second Quarter 2014 Financial Results
Marketwire - Wed Aug 27, 8:04PM CDT
MedX Health Corp. ("MedX" or the "Company"
(TSX VENTURE: MDX), dedicated to the early detection of skin cancer, announced its results for the three and six months ended June 30, 2014, which are also available on SEDAR (www.sedar.com). MedX Health Corp. Announces Approval of Debt Settlement and AGM Results
Marketwire - Wed Jun 25, 9:40PM CDT
MedX Health Corp. ("MedX" or the "Company"
(TSX VENTURE: MDX) announces that at its Annual and Special Meeting of Shareholders held on June 24, 2014, all resolutions proposed to shareholders were duly passed, including the approval of the issuance of 1,742,415 common shares relating to a settlement in November, 2013 of $435,603 of debt due to insiders of the Company. During the meeting, Gary Van Nest, David Hennigar, Steven Guillen, Ken McKay and Robert von der Porten were re-elected to the Board of Directors. MedX Health Corp. Announces Extension of Private Placement
Marketwire - Mon Mar 24, 6:40PM CDT
MedX Health Corp. ("MedX" or the "Company"
(TSX VENTURE: MDX) announces that it has extended, to April 11, 2014, the date for closing of a further tranche of the private placement of units ("Unit(s)" , in respect of which the first tranche, which raised $565,000, was closed on March 19, 2014. As previously, Trapeze Capital Corp., is acting as lead agent (the "Agent" . Each Unit comprises one common share and one share purchase warrant (a "Warrant" at $0.10 per Unit. Each Warrant entitles the holder to purchase one additional common share during the period expiring two years following closing at $0.20 per share. MedX will pay the Agent a cash commission of 8% of cash raised, subject to a reduced rate in respect of subscribers on the "President's List", and will issue broker warrants to the Agent equal in number to 8% of the Units issued. Each broker warrant will be exercisable at $0.10 to acquire a unit comprising one common share and one share purchase warrant exercisable to acquire an additional common share from treasury at an exercise price of $0.20; the broker warrants and the share purchase warrants underlying the broker warrants will expire two years after the closing of the placement. Any shares comprised in the Units and the Warrants and any shares issued on exercise of the Warrants or the broker warrants or the share purchase warrants underlying the units in the broker warrants will be restricted from trading for a period of four months and one day from the date of closing of the issue. MedX Health Corp. Announces Closing of First Tranche of Private Placement
Marketwire - Wed Mar 19, 5:16PM CDT
MedX Health Corp. ("MedX" or the "Company"
(TSX VENTURE: MDX) announces that it has closed on a first tranche of a private placement, as previously announced on January 22, 2014. Trapeze Capital Corp., acted as lead agent (the "Agent" , to raise gross proceeds of up to $2.0 million, from accredited investors, on a reasonable efforts basis through a private placement of Units. The first tranche which was closed today, raised gross proceeds of $565,000 to its treasury by issuance of 5,650,000 units, comprising 5,650,000 common shares and 5,650,000 share purchase warrants ("Warrants" at $0.10 per unit. Each Warrant entitles the holder to purchase one additional common share during the period expiring March 19, 2016, at $0.20 per share. The securities issued through the private placement were subscribed for by accredited investors, and are restricted from trading before July 20, 2014. At closing, MedX paid the Agent a cash commission of $24,200, and issued 452,000 broker warrants to the Agent. Each broker warrant will be exercisable at $0.10 to acquire a unit comprising one common share and one share purchase warrant exercisable to acquire an additional common share from treasury at an exercise price of $0.20; the broker warrants and the share purchase warrants underlying the broker warrants will expire on March 19, 2016. Any shares issued on exercise of the broker warrants or the share purchase warrants underlying the units in the broker warrants will be restricted from trading until July 20, 2014. MedX Health Corp. Announces CE Mark for Its MOLEMATE(TM)/SIMSYS(TM) Skin Cancer Imaging Systems
Marketwire - Wed Feb 12, 10:50AM CST
MedX Health Corp. ("MedX" or the "Company"
(TSX VENTURE: MDX), a leader in skin cancer imaging and diagnostics, announced receipt of a CE Mark from Conformite Europeenne, which allows the Company to market its MoleMate and SIMSYS systems in Europe to dermatologists and to expand further its pharmacy-based sales channel. MedX Health Corp. Announces Brokered Private Placement
Marketwire - Wed Jan 22, 9:19AM CST
MedX Health Corp. ("MedX" or the "Company"
(TSX VENTURE: MDX) announces the engagement of Trapeze Capital Corp., as lead agent (the "Agent" , to raise gross proceeds of up to $2.0 million, from accredited investors, on a reasonable efforts basis through a private placement of Units, with each Unit comprised of one Common Share and one Common Share Purchase Warrant ('Warrant" (the "Offering" at $0.10 per Unit. Each Warrant will entitle the holder to purchase one Common Share during the period ending two years from the date of issue, at an exercise price of $0.20. MedX Health Corp. Announces Proposed Private Placement to Raise $203,000
Marketwire - Fri Dec 20, 3:36PM CST
MedX Health Corp. ("MedX" or the "Company"
(TSX VENTURE: MDX) announces that it has entered into private placement agreements with accredited investors to raise a total of $203,000 by issuance of a total of 2,030,000 Units at $0.10 per unit. Each Unit comprises one fully paid common share and one share purchase warrant; each warrant entitles the holder to purchase one additional share at the price of $0.20 during the period expiring December 31, 2014. Closing of the Placement is subject to all relevant regulatory and other consents and approvals, including acceptance by the TSX Venture Exchange. MedX Health Corp. results for the Second Quarter of fiscal 2013
CNW Group - Tue Aug 27, 10:06PM CDT
TSX Venture Symbol: MDX
MedX Health Corp. Announces Share Issuance Pursuant To Debt Settlement Agreements And Also Grant Of Stock Options
CNW Group - Fri Jul 19, 3:51PM CDT
TSX Venture Symbol: MDX
MedX Health Corp. reaches agreements to settle debts of $362,078
CNW Group - Thu Jul 04, 2:23PM CDT
TSX Venture Symbol: MDX CUSIP #: 585090
MedX Health Reports 2012 and First Quarter 2013 Financial Results
CNW Group - Fri Jun 07, 11:29AM CDT
MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser light therapy for tissue repair and pain relief have reported their revenues for 2012 and the first quarter of 2013. Please see www.SEDAR.com for the actual filings.
IIROC Trading Resumption - MDX
CNW Group - Fri May 31, 3:27PM CDT
Trading resumes in:
IIROC: Resume, OREMEX SILVER INC., MEDX HEALTH CORP.
Marketwire Canada - Fri May 31, 3:25PM CDT
Trading resumes in / Reprise des negociations pour :
